Jun. 13 at 1:06 PM
$ENSC it's worth injecting some context to ENSC's death spiral the last few years. Biotech in general has been under increasing pressure from higher interest rates and regulatory pressure. It's a sector dominated by big Pharma more than ever. To get a new drug to market and all the way through clinical stages, assuming no buyout offers, it cost over
$1 billion!
So, to be fair, the ENSC death spiral doesn't necessarily condemn the work they're doing, and doesn't totally absolve the linkage either. The risk, though, for shareholders remains regardless, especially if you get the timing wrong; that's assuming there's even a positive outcome at the finish line whenever that finish line approaches.
